Classifieds

Pfizer and Moderna are both seeking emergency use authorization for their bivalent COVID boosters for children.


















STORY AT-A-GLANCE

Pfizer and Moderna are both seeking emergency use authorization for their bivalent COVID boosters for children. Moderna is seeking authorization for children ages 6 through 17, while Pfizer's shot is for children aged 5 through 11
The U.S. Centers for Disease Control and Prevention expects the bivalent boosters will be available for children aged 5 to 11 by mid-October 2022
In the U.S., both bivalent boosters will contain mRNA against the original Wuhan strain and Omicron variants BA.4 and BA.5. (In the U.K., Moderna's booster targets the Wuhan strain and BA.1, an earlier Omicron strain no longer in circulation)
The effectiveness of Pfizer's booster is based on antibody levels in eight mice, which cannot tell you anything about the level of protection you might receive. Moderna's booster is also based on antibody levels in mice, although the exact number is unknown
When it comes to safety, there's not even mouse data. The safety is assumed based on the original shots, even though the safety data on those is shocking beyond belief. As of September 16, 2022, the U.S. Vaccine Adverse Events Reporting System (VAERS) had logged 55,733 reports of injuries and deaths in children under the age of 18

Even as more damning data are coming to light, Pfizer and Moderna are both seeking emergency use authorization (EUA) for their bivalent COVID boosters for children. Moderna is seeking authorization for children ages 6 through 17, while Pfizer's shot is for children aged 5 through 11.[1]...